151 related articles for article (PubMed ID: 9675962)
21. Increased alveolar/capillary membrane resistance to gas transfer in patients with chronic heart failure.
Puri S; Baker BL; Oakley CM; Hughes JM; Cleland JG
Br Heart J; 1994 Aug; 72(2):140-4. PubMed ID: 7917686
[TBL] [Abstract][Full Text] [Related]
22. Alveolar gas diffusion abnormalities in heart failure.
Guazzi M
J Card Fail; 2008 Oct; 14(8):695-702. PubMed ID: 18926442
[TBL] [Abstract][Full Text] [Related]
23. Influence of ACE-inhibition on salt-mediated worsening of pulmonary gas exchange in heart failure.
Guazzi M; Brambilla R; Agostoni P; Guazzi MD
Br J Clin Pharmacol; 2001 May; 51(5):482-7. PubMed ID: 11422008
[TBL] [Abstract][Full Text] [Related]
24. Impact of medical treatment on lung diffusion capacity in elderly patients with heart failure. Baseline characteristics and 1-year follow up after medical treatment.
Petersen CL; Kjaer A
Int J Cardiol; 2005 Feb; 98(3):453-7. PubMed ID: 15708179
[TBL] [Abstract][Full Text] [Related]
25. ACE-Inhibition Benefit on Lung Function in Heart Failure is Modulated by ACE Insertion/Deletion Polymorphism.
Contini M; Compagnino E; Cattadori G; Magrì D; Camera M; Apostolo A; Farina S; Palermo P; Gertow K; Tremoli E; Fiorentini C; Agostoni P
Cardiovasc Drugs Ther; 2016 Apr; 30(2):159-68. PubMed ID: 26847573
[TBL] [Abstract][Full Text] [Related]
26. Circulating plasma surfactant protein type B as biological marker of alveolar-capillary barrier damage in chronic heart failure.
Magrì D; Brioschi M; Banfi C; Schmid JP; Palermo P; Contini M; Apostolo A; Bussotti M; Tremoli E; Sciomer S; Cattadori G; Fiorentini C; Agostoni P
Circ Heart Fail; 2009 May; 2(3):175-80. PubMed ID: 19808337
[TBL] [Abstract][Full Text] [Related]
27. Sildenafil improves the alveolar-capillary function in heart failure patients.
Bussotti M; Montorsi P; Amato M; Magini A; Baldassarre D; Tantardini F; Veglia F; Agostoni P
Int J Cardiol; 2008 May; 126(1):68-72. PubMed ID: 17490765
[TBL] [Abstract][Full Text] [Related]
28. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
[TBL] [Abstract][Full Text] [Related]
29. Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery.
Schroth M; Plank C; Meissner U; Eberle KP; Weyand M; Cesnjevar R; Dötsch J; Rascher W
Pediatrics; 2006 Jul; 118(1):e76-84. PubMed ID: 16751617
[TBL] [Abstract][Full Text] [Related]
30. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure.
Guazzi M; Tumminello G; Di Marco F; Fiorentini C; Guazzi MD
J Am Coll Cardiol; 2004 Dec; 44(12):2339-48. PubMed ID: 15607396
[TBL] [Abstract][Full Text] [Related]
31. Dissociation between ACE activity and autonomic response to ACE inhibition in patients with heart failure.
Binkley PF; Nunziata E; Haas GJ; Starling RC; Leier CV; Cody RJ
Am Heart J; 2000 Jul; 140(1):34-42. PubMed ID: 10874261
[TBL] [Abstract][Full Text] [Related]
32. Body position, membrane diffusing capacity and pulmonary capillary blood volume in chronic bronchitis and pulmonary emphysema.
Chou KC; Chang SC; Chang HI; Shiao GM
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Apr; 62(4):209-16. PubMed ID: 10367481
[TBL] [Abstract][Full Text] [Related]
33. [Diffusion disorders in patients with liver cirrhosis].
Schomerus H; Hilpert P
Z Gastroenterol; 1976 May; 14(3):378-87. PubMed ID: 969781
[TBL] [Abstract][Full Text] [Related]
34. Spironolactone improves lung diffusion in chronic heart failure.
Agostoni P; Magini A; Andreini D; Contini M; Apostolo A; Bussotti M; Cattadori G; Palermo P
Eur Heart J; 2005 Jan; 26(2):159-64. PubMed ID: 15618072
[TBL] [Abstract][Full Text] [Related]
35. [Pulmonary diffusion of carbon monoxide in 2 clinical situations: bronchial asthma and diabetes mellitus].
Zamarrón C; Del Campo F; Paredes C; Rodríguez Suárez JR
An Med Interna; 2001 May; 18(5):237-42. PubMed ID: 11496557
[TBL] [Abstract][Full Text] [Related]
36. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
37. The components of the carbon monoxide diffusing capacity in man dependent on alveolar volume.
Stam H; Versprille A; Bogaard JM
Bull Eur Physiopathol Respir; 1983; 19(1):17-22. PubMed ID: 6850142
[TBL] [Abstract][Full Text] [Related]
38. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
[TBL] [Abstract][Full Text] [Related]
39. Evolving rationale for angiotensin-converting enzyme inhibition in chronic heart failure.
Banerjee A; Talreja A; Sonnenblick EH; LeJemtel TH
Mt Sinai J Med; 2003 Sep; 70(4):225-31. PubMed ID: 12968195
[TBL] [Abstract][Full Text] [Related]
40. Importance of adjusting carbon monoxide diffusing capacity (DLCO) and carbon monoxide transfer coefficient (KCO) for alveolar volume.
Johnson DC
Respir Med; 2000 Jan; 94(1):28-37. PubMed ID: 10714476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
